Cutaneous melanoma, the most aggressive form of skin cancer, is characterized by its accumulation of a large number of ...
Melanoma cells, the most aggressive form of skin cancer, produce a protein that blocks the recognition and removal of the ...
BPDCN is an aggressive hematologic malignancy with a historically poor prognosisVisualDx is a clinical decision support system used by more than ...
The Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc.
Pharmaceutical Technology on MSN8d
Menarini to enhance BPDCN detection with VisualDx’s linkThe Menarini Group, along with its subsidiary Stemline Therapeutics, has announced a partnership with VisualDx to enhance the ...
BPDCN typically presents skin lesions and may also involve bone marrow, blood, central nervous system, lymph nodes and viscera. The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC ...
A clinical trial led by researchers at Newcastle University is investigating the best way to administer a potential treatment ...
Researchers have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO. Their study shows that blocking MARCO in ...
Performing flow cytometry on PBMCs stained with antigen-presenting cell-focused markers allowed characterization of macrophages, monocytes, and dendritic ... of skin biopsies validated these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback